Chemists aim to develop a new class of antimalarials

Researchers on Wednesday unveiled the chemical structure of what could become the first in a new class of drugs to treat malaria.

It’s an early but promising step in the effort to find new ways to treat the mosquito-borne blood disease. Two of the common parasites behind the disease are increasingly developing a resistance to the antibiotics typically prescribed as treatment. Finding drugs that work in completely new ways will be critical to meeting a global goal of reducing the number of people infected with malaria by 90 percent by 2030.

GlaxoSmithKline researchers presented their work on a new type of drug known as a pyrrolidinamide at the American Chemical Society Conference in Boston.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In